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Background: In a phase III trial, older patients with acute myeloid leukemia (N¼485) received decitabine or
treatment choice (supportive care or cytarabine). This post hoc analysis examined whether baseline renal
and hepatic function and white blood cell (WBC) counts predicted response.
Methods: Baseline WBCs and renal and liver function markers were tabulated for responders/nonresponders.
Results: Nonresponders had higher mean baseline creatinine (P¼0.005). Creatinine data showed no
signiﬁcant between-group differences by treatment within responder category.
Conclusions: No relationship was found between baseline WBCs or hepatic function and response. Higher
baseline creatinine in nonresponders may not be clinically relevant.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
Acute myeloid leukemia (AML) is a common adult leukemia, with
E12,330 new cases reported annually in the United States [1] and
E18,000 new cases reported annually in the European Union [2].
While AML is more common in the elderly [3], treatments for these
patients are limited, especially for patients with poor performance
status and/or comorbidities. The US National Comprehensive Cancer
Network [3] and the European LeukemiaNet [4] recently updated their
AML treatment guidelines to include low-intensity cytarabine, 5-aza-
cytidine, and decitabine as recommended therapies for these patients.
Decitabine, a hypomethylating agent, is indicated in the US for the
treatment of de novo and secondary myelodysplastic syndrome of
all French–American–British (FAB) subtypes and for intermediate-1,
intermediate-2, and high-risk International Prognostic Scoring Sys-
tem groups [5]. In Europe, decitabine is used to treat adults aged
Z65 years with newly diagnosed or secondary AML (according to
World Health Organisation [WHO] classiﬁcation) who are not eligible
for initial treatment with standard chemotherapy [6].
A phase III trial was conducted in 485 patients aged Z65 years
with newly diagnosed AML [7]. Every 4 weeks, patients received
decitabine 20 mg/m2 (1-h intravenous infusion for 5 successive
days) or patient0s choice of treatment, with physician0s advice,
with either supportive care (SC) or cytarabine (20 mg/m2 sub-
cutaneous injection daily for 10 successive days) [7]. This post hoc
analysis of this patient population examined whether baseline
renal and hepatic function and white blood cell (WBC) counts are
associated with response to decitabine or treatment choice.
2. Materials and methods
For patients with available data, baselineWBC count and markers
of renal function (blood urea nitrogen [BUN], creatinine, and
creatinine clearance) and of hepatic function (alanine aminotrans-
ferase [ALT], aspartate aminotransferase [AST], total bilirubin, and
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/lrr
Leukemia Research Reports
2213-0489 & 2013 The Authors. Published by Elsevier Ltd.
http://dx.doi.org/10.1016/j.lrr.2013.12.001
Abbreviations: ALT, alanine aminotransferase; AML, acute myeloid leukemia; AST,
aspartate aminotransferase; BUN, blood urea nitrogen; CR, complete response; CRi,
complete response with incomplete blood count recovery; ECOG PS, Eastern
Cooperative Oncology Group Performance Status; FAB, French–American–British
classiﬁcation; PR, partial remission; SC, supportive care; WBC, white blood cell
☆☆Clinicaltrials.gov identiﬁer: NCT00260832.
These data were presented in part at the Annual Meeting of the American Society
of Clinical Oncology, June 1–5, 2012, in Chicago, IL (abstract 6632).
n Correspondence to: Nantes University Hospital, CHU Hôtel Dieu, Nantes Cedex 1,
44093 France. Tel.: þ33 40083271; fax: þ33 40083250.
E-mail address: jacques.delaunay@chu-nantes.fr (J. Delaunay).
Leukemia Research Reports 3 (2014) 17–20
Open access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.
albumin) were compared for patients with and without a response
to decitabine or treatment choice. Response was deﬁned as mor-
phologic complete remission (CR), CR with incomplete blood count
recovery (CRi), or partial remission (PR), with morphologic CR
deﬁned per the International Working Group 2003 criteria [7,8].
Comparisons between responders and nonresponders were made
and P values calculated using a 2-sided t test assuming unequal
group variances (signiﬁcance level o0.05). Creatinine levels were
also analyzed at baseline and day 1 of each cycle, stratiﬁed by
response and treatment group, using a 2-sided t test assuming
unequal group variances.
Baseline creatinine levels were analyzed using logistic regres-
sion analysis based on responders (CRþCRiþPR) vs nonrespon-
ders, Eastern Cooperative Oncology Group Performance Status
(ECOG PS) Z2 vs 0–1, and FAB subtype M4/M4eos/M5 vs others
(excluding patients with missing FAB subtypes).
3. Results
A total of 485 patients were randomized to either decitabine
(n¼242) or treatment choice (n¼243) in the phase 3 trial [7].
At baseline, the median age of patients was 73 years (range, 64–89
years) in the decitabine group and 73 years (range, 64–91 years) in
the treatment choice group. In the decitabine and treatment
choice groups, respectively, median time since AML diagnosis
was 14 days (range, 3–346) and 15 days (range, 0–398), and 36%
and 35% of patients had secondary AML. In the decitabine group,
44% of patients had more than 50% bone marrow blasts and
median white blood cell count was 3.10 (0.3–127.0) 109/L. In the
treatment choice group, 42% of patients had more than 50% bone
marrow blasts and median white blood cell count was 3.69 (0.5–
80.9) 109/L. In each group, 36% of patients had poor-risk cytoge-
netics [7].
Overall, 102 of 485 patients (21.2%) were responders (CRþ
CRiþPR), including 68 of 242 patients (28.1%) in the decitabine
group and 34 of 243 patients (14.0%) in the treatment choice
group.
Baseline WBC count and baseline measures of hepatic and renal
function for responders and nonresponders are shown in Table 1.
No relationship was evident between responders to decitabine or
treatment choice and baseline WBC counts, or between responders
and baseline measures of hepatic function (ALT, AST, total bilirubin,
and albumin). Regarding renal function (BUN, creatinine, creatinine
clearance), nonresponders had a signiﬁcantly higher mean baseline
creatinine level compared with responders (86.78 vs 80.23 μmol/L,
respectively; P¼0.005), and correspondingly lower, although not
signiﬁcantly, creatinine clearance (68.35 vs 72.42 μmol/L, respec-
tively; P¼0.067). However, no signiﬁcant difference between non-
responders and responders was noted in mean baseline BUN (6.97 vs
6.48 mmol/L, respectively; P¼0.067) [7].
An analysis was also conducted on creatinine data for respon-
ders and nonresponders by treatment group (decitabine vs treat-
ment choice). Mean baseline creatinine levels (7 standard
deviation) by treatment group were 78.81715.78 μmol/L for
decitabine responders (n¼68) and 83.06723.94 μmol/L for treat-
ment choice responders (n¼34). Corresponding levels for non-
responders were 85.78726.99 μmol/L for decitabine (n¼171) and
87.62727.19 μmol/L for treatment choice (n¼206). No signiﬁcant
differences were seen when treatment groups were compared
within responder categories.
Changes in creatinine levels over time by response to decita-
bine or treatment choice (Fig. 1) showed no clear trends or
differences in change from baseline in creatinine levels between
responders and nonresponders by treatment group.
Logistic regression analysis showed that if baseline creatinine
levels increased 1 unit, the odds of achieving a response were
0.988. Additionally, patients with “other” FAB classiﬁcations were
less likely than patients with M4/M4E0/M5 to respond (odds
ratio¼0.807) to treatment, and patients with ECOG PS Z2 were
less likely to respond than patients with ECOG PS 0–1 (odds
ratio¼0.861). Compared with patients receiving SC, patients
receiving decitabine were 3.144 times more likely to respond,
and patients receiving cytarabine were 1.44 times more likely to
respond.
Table 1
Relationship between response to decitabine or treatment choice and baseline
white blood cell count, hepatic function (ALT, AST, bilirubin, and albumin), and
renal function (BUN and creatinine) in older patients with acute myeloid leukemia.
Parameter Nonresponder to
Decitabine or
Treatment Choicea
Responder to
Decitabine or
Treatment Choicea
(CRþCRiþPR)
P
valueb
WBC (109/L)
N 372 101
Mean (SD) 9.25 (13.98) 7.02 (12.25) 0.117
Median
(range)
4 (0.3–127) 3 (0.4–96)
ALT (U/L)
N 372 100
Mean (SD) 25.32 (35.53) 20.79 (14.53) 0.054
Median
(range)
18 (5–614) 17 (6–103)
AST (U/L)
N 371 101
Mean (SD) 23.82 (15.93) 21.74 (9.84) 0.106
Median
(range)
20 (5–203) 18 (9–65)
Total bilirubin
(μmol/L)
N 376 100
Mean (SD) 10.00 (5.06) 10.8 (5.20) 0.174
Median
(range)
9 (3–33) 10 (3–29)
Albumin (g/L)
N 377 102
Mean (SD) 34.18 (5.47) 35.07 (5.34) 0.140
Median
(range)
35 (19–48) 36 (16–44)
BUN (mmol/L)
N 377 102
Mean (SD) 6.97 (2.65) 6.48 (2.27) 0.067
Median
(range)
6 (1–23) 6 (3–20)
Creatinine
(μmol/L)
N 377 102
Mean (SD) 86.78 (27.08) 80.23 (18.88) 0.005
Median
(range)
81 (38–254) 78 (44–169)
CrCL (mL/min)c
N 377 102
Mean (SD) 68.35 (19.32) 72.42 (19.83) 0.067
Median
(range)
67 (23–138) 67 (33–133)
ALT, alanine aminotransferase; AML, acute myeloid leukemia; AST, aspartate
aminotransferase; BUN, blood urea nitrogen; CR, complete remission; CRi, CR with
incomplete blood count recovery; CrCL, creatinine clearance; PR, partial remission;
SD, standard deviation; WBC, white blood cell.
a Either supportive care or cytarabine.
b 2-sided t test assuming unequal group variances.
c Calculated using the Cockcroft–Gault method.
J. Delaunay et al. / Leukemia Research Reports 3 (2014) 17–2018
4. Discussion
This post hoc analysis of data from a large phase 3 trial in older
patients with AML [7] suggests that no relationship exists between
baseline WBC count or hepatic function and response to treatment
with decitabine or patient0s treatment choice of either supportive
care or cytarabine. In contrast, another study of older patients with
AML reported that higher peripheral blood blast counts were
associated with poorer response rates to decitabine [9]. Regarding
renal function, although baseline BUN and creatinine clearance had
no effect on response to treatment with decitabine or treatment
choice, higher mean creatinine levels in nonresponders across both
treatment groups suggested a possible prognostic relationship. How-
ever, the clinical relevance of this result is questionable. Other
explanations might be patient-related, e.g., comorbidities or poor
physical condition, and patients who have AML with a high mono-
cytic component may have increased creatinine at diagnosis [10].
A logistic regression analysis of confounding factors and creatinine
levels conﬁrmed that patients receiving SC were less likely to respond
as creatinine levels increased, as were patients with an ECOG PS Z2.
No notable differences were found in creatinine levels or in
change from baseline between responders and nonresponders to
decitabine or treatment choice in these older patients with AML,
suggesting that renal function did not adversely affect response to
decitabine. Further studies may clarify whether there is any
relationship between creatinine levels in older patients with
AML who do not respond to decitabine or to treatment choice of
supportive care or cytarabine.
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